{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-018277","form_type":"8-K","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.618223+00:00","generated_at":"2026-05-21T23:03:42.354517+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Belapectin shows 49.3% reduction in new varices in MASH cirrhosis patients at EASL 2025","bullets":["Belapectin 2 mg/kg reduced new varices by 49.3% vs placebo (p=0.04) in per-protocol population (n=287).","Only 4.3% of 2 mg/kg group had >10 kPa liver stiffness increase vs 12.5% placebo (p=0.02).","Safety profile comparable to placebo; no drug-related serious adverse events reported.","NAVIGATE trial: 355 patients randomized 1:1:1 to belapectin 2/4 mg/kg or placebo every other week for 18 months.","Data presented as late-breaking oral at EASL 2025 Congress on May 10, 2025 in Amsterdam."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-018277","json":"https://secwatch.observer/filing/0001140361-25-018277.json","markdown":"https://secwatch.observer/filing/0001140361-25-018277.md","text":"https://secwatch.observer/filing/0001140361-25-018277.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036125018277/0001140361-25-018277-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036125018277/ef20048562_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T23:03:42.354517+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}